José Manuel Vázquez-Comendador, María Mateos Seirul-Lo, María Martínez-Urbistondo, Nuria Miguel-Ontañón, Antonio González-Guzmán, Román Fernández-Guitián, Raquel Castejón, Pedro Durán-Del Campo, Pablo Tutor, Susana Mellor-Pita, Víctor Moreno-Torres
{"title":"Sjögren综合征患者中卵巢癌、小肠肿瘤、b细胞和粘膜相关淋巴组织淋巴瘤的死亡率更高","authors":"José Manuel Vázquez-Comendador, María Mateos Seirul-Lo, María Martínez-Urbistondo, Nuria Miguel-Ontañón, Antonio González-Guzmán, Román Fernández-Guitián, Raquel Castejón, Pedro Durán-Del Campo, Pablo Tutor, Susana Mellor-Pita, Víctor Moreno-Torres","doi":"10.1097/RHU.0000000000002169","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the impact of the different types of neoplasms and lineages on Sjögren syndrome (SjS) patient mortality.</p><p><strong>Methods: </strong>Medical records review study based on the Spanish Hospital Discharge Database and the International Classification of Diseases, Tenth Revision, Clinical Modification coding list. The neoplasm-related deaths in SjS patients with the general population during the period 2016-2019 were compared. A binary logistic regression analysis considering age, sex, tobacco use, and alcohol use was performed to determine the impact of SjS on the risk of dying from each neoplasm group and lineage.</p><p><strong>Results: </strong>In the period studied, 705,557 in-hospital deaths were certified in Spain, 139,531 (19.8%) from neoplasms. Neoplasms surpassed SjS activity as a cause of mortality in primary SjS patients (11.3% vs. 1.6%, p < 0.001). SjS patients presented higher mortality rates from small bowel carcinoma (0.3% vs. 1.8%; odds ratio [OR], 5.41; 95% confidence interval [CI], 1.33-22) and gynecological neoplasms (6.4% vs. 3%; OR, 2.13; 95% CI, 1.01-4.58), related to ovarian carcinomas (4.6% vs. 1.3%; OR, 3.65; 95% CI, 1.48-8.97), than the general population. Hematological neoplasm-related deaths were more prevalent in SjS patients than in the non-SjS population (18.3% vs. 8.9%; OR, 2.04; 95% CI, 1.25-3.31), mostly attributable to the higher proportion of deaths from B-cell non-Hodgkin lymphoma (8.3% vs. 2.5%; OR, 3.04; 95% CI, 1.54-6.03) and mucosa-associated lymphoid tissue lymphoma (1.8% vs. 0.1%; OR, 70.17; 95% CI, 16.61-296.36).</p><p><strong>Conclusion: </strong>SjS patients face an elevated risk of mortality from small bowel neoplasms, ovarian carcinomas, and B-cell and mucosa-associated lymphoid tissue lymphoma compared with the general Spanish population. Apart from developing approaches to mitigate their occurrence, it is crucial to explore thoroughly and consider the implementation of targeted early-detection programs for these specific conditions.</p>","PeriodicalId":14745,"journal":{"name":"JCR: Journal of Clinical Rheumatology","volume":" ","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Higher Mortality Risk From Ovarian Carcinomas, Small Bowel Neoplasms, and B-Cell and Mucosa-Associated Lymphoid Tissue Lymphomas in Sjögren Syndrome Patients.\",\"authors\":\"José Manuel Vázquez-Comendador, María Mateos Seirul-Lo, María Martínez-Urbistondo, Nuria Miguel-Ontañón, Antonio González-Guzmán, Román Fernández-Guitián, Raquel Castejón, Pedro Durán-Del Campo, Pablo Tutor, Susana Mellor-Pita, Víctor Moreno-Torres\",\"doi\":\"10.1097/RHU.0000000000002169\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To evaluate the impact of the different types of neoplasms and lineages on Sjögren syndrome (SjS) patient mortality.</p><p><strong>Methods: </strong>Medical records review study based on the Spanish Hospital Discharge Database and the International Classification of Diseases, Tenth Revision, Clinical Modification coding list. The neoplasm-related deaths in SjS patients with the general population during the period 2016-2019 were compared. A binary logistic regression analysis considering age, sex, tobacco use, and alcohol use was performed to determine the impact of SjS on the risk of dying from each neoplasm group and lineage.</p><p><strong>Results: </strong>In the period studied, 705,557 in-hospital deaths were certified in Spain, 139,531 (19.8%) from neoplasms. Neoplasms surpassed SjS activity as a cause of mortality in primary SjS patients (11.3% vs. 1.6%, p < 0.001). SjS patients presented higher mortality rates from small bowel carcinoma (0.3% vs. 1.8%; odds ratio [OR], 5.41; 95% confidence interval [CI], 1.33-22) and gynecological neoplasms (6.4% vs. 3%; OR, 2.13; 95% CI, 1.01-4.58), related to ovarian carcinomas (4.6% vs. 1.3%; OR, 3.65; 95% CI, 1.48-8.97), than the general population. Hematological neoplasm-related deaths were more prevalent in SjS patients than in the non-SjS population (18.3% vs. 8.9%; OR, 2.04; 95% CI, 1.25-3.31), mostly attributable to the higher proportion of deaths from B-cell non-Hodgkin lymphoma (8.3% vs. 2.5%; OR, 3.04; 95% CI, 1.54-6.03) and mucosa-associated lymphoid tissue lymphoma (1.8% vs. 0.1%; OR, 70.17; 95% CI, 16.61-296.36).</p><p><strong>Conclusion: </strong>SjS patients face an elevated risk of mortality from small bowel neoplasms, ovarian carcinomas, and B-cell and mucosa-associated lymphoid tissue lymphoma compared with the general Spanish population. Apart from developing approaches to mitigate their occurrence, it is crucial to explore thoroughly and consider the implementation of targeted early-detection programs for these specific conditions.</p>\",\"PeriodicalId\":14745,\"journal\":{\"name\":\"JCR: Journal of Clinical Rheumatology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2024-11-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JCR: Journal of Clinical Rheumatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/RHU.0000000000002169\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JCR: Journal of Clinical Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/RHU.0000000000002169","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的：探讨不同肿瘤类型和谱系对Sjögren综合征（SjS）患者死亡率的影响。方法：基于西班牙医院出院数据库和《国际疾病分类第十次修订版临床修改编码表》的病历回顾研究。比较2016-2019年期间SjS患者与普通人群的肿瘤相关死亡情况。通过考虑年龄、性别、吸烟和饮酒情况的二元logistic回归分析，确定SjS对每个肿瘤组和谱系死亡风险的影响。结果：在研究期间，西班牙有705,557例住院死亡，其中139,531例（19.8%）死于肿瘤。在原发性SjS患者中，肿瘤超过SjS活动成为死亡原因（11.3%比1.6%,p < 0.001）。SjS患者的小肠癌死亡率更高(0.3% vs. 1.8%；优势比[OR]， 5.41；95%可信区间[CI]， 1.33-22)和妇科肿瘤(6.4% vs. 3%；或者,2.13;95% CI, 1.01-4.58)，与卵巢癌相关(4.6% vs. 1.3%；或者,3.65;95% CI, 1.48-8.97)，高于一般人群。血液肿瘤相关死亡在SjS患者中比在非SjS人群中更为普遍(18.3%比8.9%；或者,2.04;95% CI, 1.25-3.31)，主要归因于b细胞非霍奇金淋巴瘤死亡率较高(8.3%比2.5%；或者,3.04;95% CI, 1.54-6.03)和粘膜相关淋巴组织淋巴瘤(1.8% vs. 0.1%；或者,70.17;95% ci, 16.61-296.36)。结论：与西班牙普通人群相比，SjS患者面临着因小肠肿瘤、卵巢癌、b细胞和粘膜相关淋巴组织淋巴瘤而死亡的风险升高。除了开发减少其发生的方法外，对这些特定情况进行彻底探索和考虑实施有针对性的早期检测计划至关重要。
Higher Mortality Risk From Ovarian Carcinomas, Small Bowel Neoplasms, and B-Cell and Mucosa-Associated Lymphoid Tissue Lymphomas in Sjögren Syndrome Patients.
Objective: To evaluate the impact of the different types of neoplasms and lineages on Sjögren syndrome (SjS) patient mortality.
Methods: Medical records review study based on the Spanish Hospital Discharge Database and the International Classification of Diseases, Tenth Revision, Clinical Modification coding list. The neoplasm-related deaths in SjS patients with the general population during the period 2016-2019 were compared. A binary logistic regression analysis considering age, sex, tobacco use, and alcohol use was performed to determine the impact of SjS on the risk of dying from each neoplasm group and lineage.
Results: In the period studied, 705,557 in-hospital deaths were certified in Spain, 139,531 (19.8%) from neoplasms. Neoplasms surpassed SjS activity as a cause of mortality in primary SjS patients (11.3% vs. 1.6%, p < 0.001). SjS patients presented higher mortality rates from small bowel carcinoma (0.3% vs. 1.8%; odds ratio [OR], 5.41; 95% confidence interval [CI], 1.33-22) and gynecological neoplasms (6.4% vs. 3%; OR, 2.13; 95% CI, 1.01-4.58), related to ovarian carcinomas (4.6% vs. 1.3%; OR, 3.65; 95% CI, 1.48-8.97), than the general population. Hematological neoplasm-related deaths were more prevalent in SjS patients than in the non-SjS population (18.3% vs. 8.9%; OR, 2.04; 95% CI, 1.25-3.31), mostly attributable to the higher proportion of deaths from B-cell non-Hodgkin lymphoma (8.3% vs. 2.5%; OR, 3.04; 95% CI, 1.54-6.03) and mucosa-associated lymphoid tissue lymphoma (1.8% vs. 0.1%; OR, 70.17; 95% CI, 16.61-296.36).
Conclusion: SjS patients face an elevated risk of mortality from small bowel neoplasms, ovarian carcinomas, and B-cell and mucosa-associated lymphoid tissue lymphoma compared with the general Spanish population. Apart from developing approaches to mitigate their occurrence, it is crucial to explore thoroughly and consider the implementation of targeted early-detection programs for these specific conditions.
期刊介绍：
JCR: Journal of Clinical Rheumatology the peer-reviewed, bimonthly journal that rheumatologists asked for. Each issue contains practical information on patient care in a clinically oriented, easy-to-read format. Our commitment is to timely, relevant coverage of the topics and issues shaping current practice. We pack each issue with original articles, case reports, reviews, brief reports, expert commentary, letters to the editor, and more. This is where you''ll find the answers to tough patient management issues as well as the latest information about technological advances affecting your practice.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
